Clinical trials: Nonsmall Cell Lung Cancer Stage III
Non Small Cell Lung Cancer Stage III, Immunotherapy
Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy
The predictive value of the microbiome (throat swabs, stool and of bronchial samples) to identify patients who will relapse during durvalumab treatment after CRT (False negative Rate) at 6 months.
- Trial name
- Prediction (NCT04711330)
- Where
- 6 sites in Belgium, Netherlands
- Volunteers
- 126 people
- Sponsor
- Leiden University Medical Center
Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well platinum doublet chemotherapy and proton beam radiation therapy work in treating patients with stage II-III non-small cell lung cancer that cannot be removed by surgery…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
- Trial name
- NCT03132532
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
ALK Gene Rearrangement, EGFR Gene Mutation
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
This phase I trial studies the side effects of ipilimumab and nivolumab in combination with radiation therapy, and to see how well they work in treating patients with stage II-III non-small cell lung cancer.
- Conditions
- ALK Gene Rearrangement, EGFR Gene Mutation, Locally Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma
- Trial name
- NCT04013542
- Testing
- Ipilimumab, Nivolumab, Radiation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Stage IIIA Lung Cancer
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled.
- Conditions
- Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer
- Trial name
- ATHENEA (NCT07153445)
- Testing
- Atezolizumab, Paclitaxel, Carboplatin
- Where
- 21 sites in Spain
- Volunteers
- 97 people
- Sponsor
- Fundación GECP
Non-small Cell Lung Cancer
A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer
This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage III non-small cell lung cancer.
- Trial name
- NCT04958993
- Testing
- Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Shandong Cancer Hospital and Institute
Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired.
- Conditions
- Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT07104630
- Testing
- Pulmonary Rehabilitation (PR), No intervention: Usual care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Non-small-cell Lung
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care.
- Trial name
- NCT00036647
- Testing
- Tarceva (erlotinib HCl, OSI-774 )
- Where
- 97 sites in United States, Argentina and 15 more
- Volunteers
- 731 people
- Sponsor
- OSI Pharmaceuticals
NSCLC (Non-small Cell Lung Cancer)
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
This phase II trial employs a prospective, randomized, parallel-group design to evaluate the efficacy and safety of hypofractionated radiotherapy combined with tislelizumab and surufatinib.
- Trial name
- NCT07609121
- Testing
- Radiotherapy, Concurrent chemotherapy, Tislelizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III
Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients
The purpose of this research study is to find out what effects (good or bad) may come from a new way of doing radiation therapy for lung cancer.
- Trial name
- NCT04398199
- Testing
- Hypofractionated Radiation Therapy, Radiation Boost
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Carcinoma, Non-Small-Cell Lung
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins…
- Trial name
- NCT01909752
- Testing
- Cyclophosphamide, DRibble vaccine, Imiquimod
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UbiVac
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III…
- Trial name
- NCT07122687
- Testing
- Pemetrexed, Cisplatin, IBI363
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without…
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00003313
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- 264 sites in United States, Canada
- Volunteers
- 243 people
- Sponsor
- Radiation Therapy Oncology Group
Non-small Cell Lung Cancer
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung…
- Trial name
- START (NCT00409188)
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide
- Where
- 290 sites in United States, Argentina and 31 more
- Volunteers
- 1,513 people
- Sponsor
- EMD Serono
Non-small Cell Lung Cancer
Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer
To evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
- Trial name
- DP-EN-RT (NCT01218594)
- Testing
- Endostatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Stage IIIA Non-small Cell Lung Cancer
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue in patients with…
- Trial name
- NCT01076231
- Testing
- proton beam radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00310154
- Testing
- docetaxel, gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer, Malignant Mesothelioma
Alanosine in Treating Patients With Cancer
RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
- Trial name
- NCT00062283
- Testing
- L-alanosine
- Where
- 12 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and Lobectomy
The role of sublobar resection(Wedge resection or anatomic segmentectomy) for small(≤ 2cm) early stage non-small cell lung cancer has been studied by Lung Cancer Study Group and is being studied by several ongoing trials.
- Trial name
- STEPS (NCT02360761)
- Testing
- VATS, Thoracotomy
- Where
- 6 sites in China
- Volunteers
- 339 people
- Sponsor
- Peking University People's Hospital
Lung Cancer
Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
RATIONALE: Studying quality-of-life in patients undergoing cancer treatment may help identify the intermediate and long-term effects of treatment on patients with cancer.
- Trial name
- NCT00242983
- Testing
- quality-of-life assessment
- Where
- 21 sites in Japan
- Sponsor
- National Hospital Organization Kinki-chuo Chest Medical Center
Melanoma (Skin), Non-Small-Cell Lung Carcinoma
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
From Protocol v3.0 dated 16Jun2022. This is an international, multicenter, open-label, multiple cohort, First in Human, phase 1b clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any…
- Trial name
- NCT04990479
- Testing
- GAd-PEV, MVA-PEV
- Where
- 7 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Nouscom SRL